Aricept vs Namenda

How they're similar

Aricept and Namenda are both symptomatic treatments for Alzheimer's disease. They ease some symptoms while the disease continues underneath. Neither one modifies the disease, meaning neither slows or reverses the underlying loss of neurons.

• Both are taken every day and both need consistent use to keep any benefit going.
• Both show modest effect sizes in trials. On cognitive rating scales like ADAS-cog, the average improvement is about 3 to 4 points, and much of the effect looks like stabilization for a period rather than a return of lost function.
• Both are commonly used in moderate to severe Alzheimer's, sometimes together.
• Both need to be tapered off carefully if they're stopped, because rapid changes can worsen function.
• Both are widely available as generics.

The overlap is really at the level of purpose. Two brand-name medications for the same disease, each giving a fairly small nudge in the right direction. Combining them can offer a somewhat larger benefit for people in the moderate to severe range.

How they differ

The mechanism is different, the approved stages are different, and the side effect profiles are different. The table sums up the core points.

Aricept was the first cholinesterase inhibitor to become widely used in Alzheimer's care. Its mechanism is to slow the breakdown of acetylcholine, a chemical messenger that's lost early in the disease. When the enzyme acetylcholinesterase is blocked, more acetylcholine stays available at nerve endings, and that supports memory and attention to a modest degree.

Namenda works on a completely different system. Glutamate is the brain's main excitatory messenger, and in Alzheimer's, glutamate signaling through NMDA receptors seems to run at a low chronic level of overactivity that damages neurons over time. Namenda is a low-affinity blocker of these receptors, meaning it dampens the chronic noise without shutting down the normal signals that are needed for learning.

Approved stages come from where each drug was studied. Aricept is approved across the range of Alzheimer's from mild to severe. Namenda's evidence is in the moderate to severe range, so that's where its approval sits. Namenda is sometimes tried off-label earlier, but the strongest data for it is in more advanced disease.

Dosing rhythms differ. Aricept starts at 5 mg once daily, usually at bedtime, and after four to six weeks the dose is often raised to 10 mg. A 23 mg version exists for severe Alzheimer's, and it's a separate formulation, not two tablets combined. Namenda starts low at 5 mg daily and is titrated up by 5 mg each week to reach 10 mg twice daily. Namenda XR is dosed once daily and can reach 28 mg. The slow titration is important for keeping side effects manageable.

Namzaric is a fixed combination product that puts memantine and donepezil in one capsule, and it's often used once someone is stable on both drugs separately. Consolidating to one capsule can help with adherence in a household where medication management is already complicated.

Side effect tendencies

Side effects are one of the main things that separates these two drugs.

Aricept's side effects come from raising acetylcholine everywhere in the body, not just in the brain. That means the gut, the heart, and the sleep system all feel it. Nausea, diarrhea, decreased appetite, and weight loss are the ones families notice most. Slower heart rate is a real concern, especially in someone already on a beta-blocker or with a known conduction issue, and rarely it can cause fainting. Vivid dreams and nightmares happen for some people, which is one reason some prescribers switch dosing from bedtime to morning if sleep is disrupted. Muscle cramps and increased urination round out the common list. Side effects mostly show up early and either fade or lead to a dose adjustment. Some people just can't tolerate any cholinesterase inhibitor, and that's a normal outcome to identify and work around.

Namenda is much better tolerated overall. Dizziness is the most common complaint, and it usually settles as the dose is titrated. Headache, confusion, and constipation come up but aren't often severe. The confusion piece can be tricky, because it looks like the disease itself, and slowing down the titration usually helps. Namenda isn't cleared by the liver in the usual way, so it has fewer drug interactions. It is cleared by the kidneys, so the dose needs to be reduced in significant kidney disease.

Bradycardia and syncope are real reasons a prescriber might hesitate on Aricept in a frail older adult, or in someone with heart block or sick sinus. In those settings, Namenda may be a safer place to start if the disease has reached the moderate stage.

What tips the choice

For someone with mild Alzheimer's, Aricept is the practical option. Namenda isn't approved for that stage and the evidence for it there is weaker.

For someone with moderate to severe Alzheimer's, both are on the table, and using them together is common. Namzaric combines memantine and donepezil in one capsule, which can simplify a complicated medication list. If side effects on Aricept are a problem, Namenda alone is a reasonable path. If someone is already stable on Aricept and enters the moderate stage, adding Namenda is a standard step.

Heart rhythm history matters. In someone with symptomatic bradycardia, sick sinus, or a history of syncope, Namenda avoids the vagal effects that Aricept can cause. Similarly, in someone with an active GI disorder or ongoing weight loss, Namenda's better tolerability can tip the scale.

Kidney function matters for Namenda. In moderate to severe kidney disease, the dose is halved. Aricept doesn't need the same kind of renal adjustment.

Cost is generally not the deciding factor, since both are available as inexpensive generics. Formularies and prior authorizations can still come into play, and families sometimes find one drug on their plan without any hassle and the other with some paperwork.

Expectations matter more than any of this. Families who understand that these medications offer modest, sometimes hard to see benefits, and that neither is a cure, have a much easier time with the treatment plan. If the expectation is that memory will come back, disappointment is close behind.

Common questions

Do Aricept and Namenda actually work? They work in the sense that trials show a real, measurable effect on cognitive scores and daily function, and that effect is modest. For some people it's noticeable to family and clinicians. For others it looks more like a slower decline than what was expected. Neither drug reverses the disease, and the benefit tends to fade as the disease progresses.

Can Aricept and Namenda be taken together? Yes, and it's common in moderate to severe Alzheimer's. The combination has better evidence than either drug alone in that range. Namzaric is a single capsule that combines both, which some families prefer for simplicity.

Which one has fewer side effects? Namenda, on average. Aricept's cholinergic effects on the gut and heart are the main issue. Namenda's most common side effects are dizziness and headache, and both often settle with a slower titration.

When should these medications be stopped? There isn't one right answer. Some families and clinicians continue them into late-stage disease. Others stop them when the person can no longer swallow safely, when side effects outweigh any perceived benefit, or when goals of care shift toward comfort. Stopping should be discussed with the prescriber, and it's usually done gradually rather than abruptly.

Are the brand names still available, or is it all generic now? Both Aricept and Namenda have generic versions that are widely used. The brand-name versions are still around, but for most people the generic is what shows up at the pharmacy. Namzaric, the combined memantine-donepezil capsule, also has a generic version.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes. This is not medical advice.

1. U.S. Food and Drug Administration. Donepezil (Aricept) prescribing information.
2. U.S. Food and Drug Administration. Memantine (Namenda) prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute on Aging. Alzheimer's disease medications.